サーブ・バイオファーマ

CERV Biopharma is a Tokyo-based biotechnology startup dedicated to advancing drug discovery through its proprietary CERV (Cell-based Expression of Recombinant Virus) platform. The company focuses on the development of VHH antibodies, also known as nanobodies, and therapeutic peptides, which offer advantages in stability and tissue penetration over traditional antibodies. Their technology enables high-throughput screening and selection of high-affinity binders against challenging therapeutic targets that are often considered undruggable. CERV Biopharma primarily targets applications in oncology and infectious diseases, aiming to provide novel treatment options for patients with limited therapeutic alternatives.